AM-101

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
01220112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Objective To evaluate the safety and tolerability of repeated intratympanic administration of the gel-formulated NMDA receptor… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2016
2016
Regulators have yet to approve any drugs specifically for the treatment of hearing loss and related disorders — an untapped… (More)
  • table 1
Is this relevant?
2015
2015
Inhibition of cochlear N-methyl-D-aspartate (NMDA) receptors with AM-101, a small molecule antagonist delivered by intratympanic… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 3
Is this relevant?
2015
2015
BACKGROUND Accumulating evidence suggests that tinnitus may occur despite normal auditory sensitivity, probably linked to partial… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2014
2014
OBJECTIVE To evaluate the efficacy and safety of intratympanic AM-101 in patients with persistent acute inner ear tinnitus after… (More)
  • figure 1
  • table 1
  • table 2
  • table 4
  • table 3
Is this relevant?
2013
2013
Auris Medical’s CHF 47.1 ($51) million Series C funding round, disclosed on April 16 by the Basel-based company, is the latest… (More)
  • table 1
Is this relevant?
2011
2011
Effective pharmacological treatments for tinnitus have proven elusive. Emerging evidence suggests that dysregulation of cochlear… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?